Systematic review and Meta-analysis of efficacy and safety of Yangxin Dingji Capsules in treatment of arrhythmia.
10.19540/j.cnki.cjcmm.20210409.502
- Author:
Xiao-Yu WANG
1
;
Hai-Yin HU
2
;
Zhao-Chen JI
2
;
Jing-Bo ZHAI
2
;
Chun-Xiang LIU
2
;
Jun-Hua ZHANG
2
Author Information
1. Tianjin University of Traditional Chinese Medicine Tianjin 301617, China.
2. Tianjin University of Traditional Chinese Medicine Tianjin 301617, China Evidence-based Medicine Center,Tianjin University of Traditional Chinese Medicine Tianjin 301617, China.
- Publication Type:Systematic Review
- Keywords:
Chinese patent medicine;
Meta-analysis;
Yangxin Dingji Capsules;
arrhythmia;
randomized controlled trial;
systematic review
- MeSH:
Bradycardia;
Capsules;
Drugs, Chinese Herbal;
Humans;
Stroke Volume;
Ventricular Function, Left
- From:
China Journal of Chinese Materia Medica
2021;46(20):5418-5427
- CountryChina
- Language:Chinese
-
Abstract:
To systematically review the efficacy and safety of Yangxin Dingji Capsules in the treatment of arrhythmia. PubMed, EMbase, Cochrane Library, CNKI, VIP, CBM and Wanfang databases were electronically retrieved to collect randomized controlled trial(RCT) on the efficacy of Yangxin Dingji Capsules in the treatment of arrhythmia from the time of database establishment to October 20 th, 2020. Two reviewers independently screened out the literatures, input the data, and evaluated the literature quality of the included studies. RevMan 5.3 software was used for Meta-analysis. A total of 127 studies were retrieved, and 15 articles were included after screening, involving 1 371 cases, with 685 cases in the treatment group and 686 cases in the control group. Yangxin Dingji Capsules combined with anti-arrhythmia western medicine was adopted for intervention in the treatment group, while the patients in the control group were treated with the anti-arrhythmia western medicine alone. Meta-analysis results showed that in arrhythmia patients, the combination of Yangxin Dingji Capsules and conventional western medicine significantly increased the clinical efficacy(RR=1.23, 95%CI[1.17, 1.30], P<0.000 01)and left ventricular ejection fraction(MD=4.31, 95%CI[3.10, 5.52], P<0.000 01), reduced heart rate(MD=-3.79, 95%CI[-7.42,-0.15], P=0.04), left ventricular end-diastolic diameter(MD=-7.06, 95%CI[-11.91,-2.21],P=0.004), left ventricular end-systolic diameter(MD=-4.78, 95%CI[-6.63,-2.93],P<0.000 01), N-terminal B-type natriuretic peptide precursor(MD=-200.51, 95%CI[-254.52,-146.51], P<0.000 01)and high-sensitivity C-reactive protein(MD=-1.74, 95%CI[-3.23,-0.24], P=0.02), all with statistically significant differences. Compared with the control group, Yangxin Dingji Capsules had fewer adverse reactions(RR=0.53, 95%CI[0.36, 0.79], P=0.002). The existing evidences showed that Yangxin Dingji Capsules had certain effect in the treatment of arrhythmia, with a safety. However, due to the limitation in sample size, outcome measures and quality of the included studies, more high-quality studies are required to verify the above conclusion.
